Wanbury Q2 FY27 Results: Operational Recovery and Regulatory Pipeline Expansion
Wanbury Ltd 路 Press Release 路 06 Nov 2026, 7:02 pm
Wanbury Q2 FY27 Results: Operational Recovery and Regulatory Pipeline Expansion Wanbury reported standalone Q2 FY27 revenue of Rs 182.9 crore, up 14.3% YoY and 10.5% QoQ, driven by recovery from previous West Asia supply disruptions. EBITDA rose 57.9% QoQ to Rs 26.2 crore with margins expanding 431 bps QoQ to 14.3%, while PAT reached Rs 11.9 crore. Lower borrowing rates reduced finance costs to Rs 6.3 crore. Operationally, the Tanuku facility received Australia鈥檚 TGA GMP certification on 28th Oct'26, EDQM approved Rivaroxaban API, and USFDA issued multiple "No DMF Deficiency" letters.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026. 路 18 Nov 2026
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. 路 30 Oct 2026
